Zobrazeno 1 - 10 of 127 pro vyhledávání: '"S A Schreiber"'
1
DOP41 Achievement of corticosteroid-free clinical endpoints in subjects with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 trial
Autor: B E Sands, D T Rubin, J Panés, K B Gecse, Y Leung, M Goetsch, W Wang, K Shan, J Woolcott, C C Smith, K Wosik, S W Schreiber
Publikováno v: Journal of Crohn's and Colitis. 17:i106-i107
Background Achievement of corticosteroid (CS)-free remission is an important long-term outcome in ulcerative colitis (UC). Etrasimod is an investigational, once-daily, oral, selective sphingosine 1-phosphate receptor 1,4,5 (S1P1,4,5) modulator in dev
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::933d9fcc29ba77ea5c5211bad6936798
https://doi.org/10.1093/ecco-jcc/jjac190.0081
Zobrazit plný text záznamu
2
P348 Disease trajectories in ulcerative colitis: Early identification of patients with endoscopic remission at Week 52
Autor: S W Schreiber, S Danese, L Dirk, C Agboton, J F Colombel
Publikováno v: Journal of Crohn's and Colitis. 17:i485-i486
Background Clinical understanding of different disease courses in response to targeted therapies in ulcerative colitis (UC) is lacking. Symptom load over time can help to define different trajectories leading to outcome measures at week 52. This post
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::92bfd173ae13917d1538c66889d1247a
https://doi.org/10.1093/ecco-jcc/jjac190.0478
Zobrazit plný text záznamu
3
P151 Assessing comprehensive remission for Ulcerative Colitis in clinical practice: International consensus recommendations
Autor: S W Schreiber, S Danese, A Dignass, E Domènech, M Fantini, M Ferrante, J Halfvarson, A Hart, F Magro, C Lees, S Leone, M Pierik, P Field, H Schofield, L Peyrin-Biroulet
Publikováno v: Journal of Crohn's and Colitis. 17:i311-i312
Background Real-world treatment of ulcerative colitis (UC) requires a patient-centric, holistic definition of ‘comprehensive remission' that goes beyond standard regulatory definitions. In an international initiative, we reviewed aspects of UC that
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::751773d04747d4c48e99e6de6feb836f
https://doi.org/10.1093/ecco-jcc/jjac190.0281
Zobrazit plný text záznamu
4
OP04 Safety analysis of filgotinib for Ulcerative Colitis: Results from the phase 2b/3 SELECTION study and phase 3 SELECTIONLTE long-term extension study
Autor: J Hsieh, Gerhard Rogler, Edward V. Loftus, Y Zhou, U Moerch, S Zhao, S W Schreiber, C Yun, Mamoru Watanabe
Publikováno v: Journal of Crohn's and Colitis. 15:S004-S006
Background Filgotinib (FIL) is an oral preferential Janus kinase (JAK) 1 inhibitor in development for the treatment of inflammatory diseases. FIL for the treatment of moderately to severely active ulcerative colitis (UC) was evaluated in the phase 2b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e32a7ca5bf9a7747a8b0b01538cb3240
https://doi.org/10.1093/ecco-jcc/jjab075.003
Zobrazit plný text záznamu
6
Akademický článek
The Posterior Cerebral Artery and its Main Cortical Branches Identified with Noninvasive Transcranial Color-Coded Duplex Sonography
Autor: P. E. Frid, S. J. Schreiber, O. Pade, F. Doepp, J. Valdueza
Publikováno v: Ultrasound International Open, Vol 01, Iss 02, Pp E53-E57 (2015)
Purpose: To differentiate PCA segments and cortical branches by means of transcranial color-coded duplex sonography (TCCD) and to measure flow parameters at rest and during visual stimulation. Materials and Methods: 60 healthy subjects with a good a
Externí odkaz: https://doaj.org/article/28c4d57815c349059f4440bb514044e9
Zobrazit plný text záznamu
7
DOP82 Achievement of steroid-free remission in patients with moderately to severely active Crohn’s Disease during treatment with risankizumab
Autor: S W Schreiber, R Cross, R Panaccione, G D’Haens, P Bossuyt, J F Colombel, E Louis, M Dubinsky, K Kligys, E Neimark, A Song, J Zambrano, E Cheng, M Ferrante
Publikováno v: Journal of Crohn's and Colitis. 16:i125-i126
Background The efficacy and safety of risankizumab (RZB) as induction and maintenance therapy for patients with moderately to severely active Crohn’s disease (CD) has been documented. Steroid-free clinical remission is an important additional treat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::82e4338427bc250957d5c4d4dfe4299c
https://doi.org/10.1093/ecco-jcc/jjab232.121
Zobrazit plný text záznamu
8
OP26 Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
Autor: Sofie Berg, Ezequiel Neimark, Xiaomei Liao, Marc Ferrante, James O. Lindsay, S W Schreiber, A P Song, W J Sandborn, T Feng, Tadakazu Hisamatsu, David T. Rubin, Kori Wallace, J.-F. Colombel, Remo Panaccione, G R D’Haens, A Lim
Publikováno v: Journal of Crohn's and Colitis. 15:S026-S027
Background Present therapies leave an unmet need for early and effective treatment for patients with Crohn’s disease (CD). Risankizumab (RZB), a humanized immunoglobulin G1 monoclonal antibody against the p19 subunit of interleukin-23, was evaluate
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::db05e77f6a7a219b23df02d33c3e3389
https://doi.org/10.1093/ecco-jcc/jjab075.025
Zobrazit plný text záznamu
9
A GIS-Based Framework Creating Green Stormwater Infrastructure Inventory Relevant to Surface Transportation Planning
Autor: Dylan S. P. Schreiber, Qing Lu, Xiaofan Xu, Qiong Zhang
Publikováno v: Sustainability, Vol 10, Iss 12, p 4710 (2018)
Sustainability
Volume 10
Issue 12
The stormwater runoff that carries pollutants from the land adjacent to road transportation systems may impair the water environment and threaten the ecosystem and human health. A proper management approach like green stormwater infrastructure (GSI)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dbdea184ed8352a7c3d803ae18a2936
https://www.mdpi.com/2071-1050/10/12/4710
Zobrazit plný text záznamu
10
Effects of Prebiotic and Synbiotic Supplementation on Inflammatory Markers and Anthropometric Indices After Roux-en-Y Gastric Bypass
Autor: Erasmo Benício Santos de Moraes Trindade, Bruna Teles Soares Beserra, Tânia Silvia Fröde, Ricardo Fernandes, Julia Salvan da Rosa, Rafaella Cristina Dimbarre de Miranda, Michel Carlos Mocellin, Marilyn G.F. Kuntz, Cristina S. O. Schreiber, Everson Araújo Nunes
Publikováno v: Journal of Clinical Gastroenterology. 50:208-217
Background Studies have shown that prebiotics and synbiotics modulate the intestinal microbiota and may have beneficial effects on the immune response and anthropometric indices; however, the impact of the use of these supplements after bariatric sur
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::204a57065e9ff2472ef2439197f205c7
https://doi.org/10.1097/mcg.0000000000000328
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje